Although immune checkpoint inhibitors alone have not shown improved overall survival compared to chemotherapy in patients with EGFR-mutated advanced NSCLC [8], the significance of high PD-L1 expression levels has been increasingly recognized. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.